IP Library › Granted Patent US 12,428,451
Granted Patent B2
US 12,428,451 · App. 17/268,804 · Granted Sep 30, 2025

Immunoglobulin-binding protein, and affinity carrier using same

Inventors: Tomoaki Haga (Minato-ku, JP); Takashi Ichii (Minato-ku, JP); Shunsuke Onogi (Minato-ku, JP); Satoshi Nakamura (Minato-ku, JP); Toshinari Honda (Minato-ku, JP); Tomoyuki Kamide (Minato-ku, JP)
Assignees: JSR CORPORATION; JSR Life Sciences, LLC; JSR MICRO N.V.
C07K14/31B01D15/3809C07K1/22C07K16/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,428,451
App. No.
17/268,804
Granted
Sep 30, 2025
Kind
B2
Abstract

An affinity carrier may have improved alkali resistance. An immunoglobulin-binding protein containing a mutant polypeptide chain, as well as an affinity carrier containing a solid-phase carrier to which the immunoglobulin-binding protein is bound, may be a mutant polypeptide chain having an amino acid sequence having at least 85% identity to an amino acid sequence indicated by any of SEQ ID NO: 1-6 and 57-62, having a predetermined mutation, and having immunoglobulin-binding activity.

Claims (89)

1. An immunoglobulin-binding protein, comprising:

a polypeptide chain consisting of an amino acid sequence having at least 85% identity to an amino acid sequence represented by any one of SEQ ID NOs: 1 to 6, 57-59 and 61-62, wherein said amino acid sequence having at least 85% identity to any one of SEQ ID NOS: 1 to 6, 57-59 and 61-62 having a substitution of Asn with Gln at a position corresponding to position 11 of the amino acid sequence represented by SEQ ID NO: 1, 2, 3, 5, or at position 6 of the amino acid sequence represented by SEQ ID No. 4, or at position 9 of the amino acid sequence represented by SEQ ID No. 6, or at position 7 of the amino acid sequence represented by SEQ ID No. 57, 58, 59, 61, 62 and optionally having at least one mutation selected from the group consisting of (a) to (f):

(a) substitution of an amino acid residue at at least one position selected from the group consisting of positions corresponding to positions 3 and 6 of the amino acid sequence represented by SEQ ID NO: 3 with another amino acid residue, deletion of the amino acid residue at the at least one position, or insertion of another amino acid residue into a position in front of or behind the at least one position;

(b) substitution of an amino acid residue at at least one position selected from the group consisting of positions corresponding to positions 24 and 25 of the amino acid sequence represented by SEQ ID NO: 3 with another amino acid residue, deletion of the amino acid residue at the at least one position, or insertion of another amino acid residue into a position in front of or behind the at least one position;

(c) substitution of an amino acid residue at a position corresponding to position 39 of the amino acid sequence represented by SEQ ID NO: 3 with another amino acid residue, deletion of the amino acid residue at the position corresponding to position 39, or insertion of another amino acid residue into a position in front of or behind the position corresponding to position 39;

(d) substitution of an amino acid residue at a position corresponding to position 46 of the amino acid sequence represented by SEQ ID NO: 3 with another amino acid residue, deletion of the amino acid residue at the position corresponding to position 46, or insertion of another amino acid residue into a position in front of or behind the position corresponding to position 46;

(e) substitution of an amino acid residue at at least one position selected from the group consisting of positions corresponding to positions 4, 49, and 58 of the amino acid sequence represented by SEQ ID NO: 3 with another amino acid residue, deletion of the amino acid residue at the at least one position, or insertion of another amino acid residue into a position in front of or behind the at least one position; and

(f) substitution of an amino acid residue at a position corresponding to position 23 of the amino acid sequence represented by SEQ ID NO: 3 with another amino acid residue, deletion of the amino acid residue at the position corresponding to position 23, or insertion of another amino acid residue into a position in front of or behind the position corresponding to position 23.

2. The protein of claim 1 , wherein the polypeptide chain is a polypeptide chain consisting of an amino acid sequence having at least 85% identity to the amino acid sequence represented by SEQ ID NO: 3 and having the at least one mutation.

3. The protein of claim 1 , wherein the at least one mutation is selected from the group consisting of:

(a1) substitution of Asn with Gln at a position corresponding to position 3 of the amino acid sequence represented by SEQ ID NO: 3;

(a2) substitution of Asn with Ala at a position corresponding to position 3 of the amino acid sequence represented by SEQ ID NO: 3;

(a3) substitution of Asn with Asp at a position corresponding to position 3 of the amino acid sequence represented by SEQ ID NO: 3;

(a4) substitution of Asn with Gln at a position corresponding to position 6 of the amino acid sequence represented by SEQ ID NO: 3;

(a5) substitution of Asn with Ala at a position corresponding to position 6 of the amino acid sequence represented by SEQ ID NO: 3;

(a6) substitution of Asn with Asp at a position corresponding to position 6 of the amino acid sequence represented by SEQ ID NO: 3;

(b1) substitution of Glu with Asp at a position corresponding to position 24 of the amino acid sequence represented by SEQ ID NO: 3;

(b2) substitution of Glu with Asp at a position corresponding to position 25 of the amino acid sequence represented by SEQ ID NO: 3;

(c1) substitution of Ser with Lys at a position corresponding to position 39 of the amino acid sequence represented by SEQ ID NO: 3;

(c2) substitution of Ser with Arg at a position corresponding to position 39 of the amino acid sequence represented by SEQ ID NO: 3;

(d1) substitution of Ala with Asp at a position corresponding to position 46 of the amino acid sequence represented by SEQ ID NO: 3;

(d2) substitution of Ala with Glu at a position corresponding to position 46 of the amino acid sequence represented by SEQ ID NO: 3;

(d3) substitution of Ala with Lys at a position corresponding to position 46 of the amino acid sequence represented by SEQ ID NO: 3;

(d4) substitution of Ala with Arg at a position corresponding to position 46 of the amino acid sequence represented by SEQ ID NO: 3;

(e1) deletion of Lys at a position corresponding to position 4 of the amino acid sequence represented by SEQ ID NO: 3;

(e2) substitution of Lys with Arg at a position corresponding to position 49 of the amino acid sequence represented by SEQ ID NO: 3;

(e3) deletion of Lys at a position corresponding to position 58 of the amino acid sequence represented by SEQ ID NO: 3;

(e4) substitution of Lys with Arg at a position corresponding to position 58 of the amino acid sequence represented by SEQ ID NO: 3;

(f1) substitution of Thr with Arg at a position corresponding to position 23 of the amino acid sequence represented by SEQ ID NO: 3;

(f2) substitution of Thr with Leu at a position corresponding to position 23 of the amino acid sequence represented by SEQ ID NO: 3; and

(f3) substitution of Thr with Ser at a position corresponding to position 23 of the amino acid sequence represented by SEQ ID NO: 3.

4. The protein of claim 3 , wherein the at least one mutation is selected from the group consisting of:

(a1) substitution of Asn with Gln at a position corresponding to position 3 of the amino acid sequence represented by SEQ ID NO: 3;

(a2) substitution of Asn with Ala at a position corresponding to position 3 of the amino acid sequence represented by SEQ ID NO: 3;

(a3) substitution of Asn with Asp at a position corresponding to position 3 of the amino acid sequence represented by SEQ ID NO: 3;

(a4) substitution of Asn with Gln at a position corresponding to position 6 of the amino acid sequence represented by SEQ ID NO: 3;

(a5) substitution of Asn with Ala at a position corresponding to position 6 of the amino acid sequence represented by SEQ ID NO: 3;

(a6) substitution of Asn with Asp at a position corresponding to position 6 of the amino acid sequence represented by SEQ ID NO: 3;

(a23) substitution of Asns with Glns at positions corresponding to positions 3 and 6 of the amino acid sequence represented by SEQ ID NO: 3;

(a24) substitution of Asn with Ala at a position corresponding to position 3 of the amino acid sequence represented by SEQ ID NO: 3;

(a25) substitution of Asn with Asp at a position corresponding to position 3 of the amino acid sequence represented by SEQ ID NO: 3;

(a26) substitution of Asn with Asp at a position corresponding to position 6 of the amino acid sequence represented by SEQ ID NO: 3;

(a27) substitution of Asn with Asp at a position corresponding to position 3, and substitution of Asn with Asp at a position corresponding to position 6 of the amino acid sequence represented by SEQ ID NO: 3;

(a28) substitution of Asn with Ala at a position corresponding to position 3, and substitution of Asn with Asp at a position corresponding to position 6 of the amino acid sequence represented by SEQ ID NO: 3;

(b1) substitution of Glu with Asp at a position corresponding to position 24 of the amino acid sequence represented by SEQ ID NO: 3;

(b2) substitution of Glu with Asp at a position corresponding to position 25 of the amino acid sequence represented by SEQ ID NO: 3;

(c1) substitution of Ser with Lys at a position corresponding to position 39 of the amino acid sequence represented by SEQ ID NO: 3;

(c2) substitution of Ser with Arg at a position corresponding to position 39 of the amino acid sequence represented by SEQ ID NO: 3;

(d1) substitution of Ala with Asp at a position corresponding to position 46 of the amino acid sequence represented by SEQ ID NO: 3;

(d2) substitution of Ala with Glu at a position corresponding to position 46 of the amino acid sequence represented by SEQ ID NO: 3;

(d3) substitution of Ala with Lys at a position corresponding to position 46 of the amino acid sequence represented by SEQ ID NO: 3;

(d4) substitution of Ala with Arg at a position corresponding to position 46 of the amino acid sequence represented by SEQ ID NO: 3;

(e1) deletion of Lys at a position corresponding to position 4 of the amino acid sequence represented by SEQ ID NO: 3;

(e2) substitution of Lys with Arg at a position corresponding to position 49 of the amino acid sequence represented by SEQ ID NO: 3;

(e3) deletion of Lys at a position corresponding to position 58 of the amino acid sequence represented by SEQ ID NO: 3;

(e4) substitution of Lys with Arg at a position corresponding to position 58 of the amino acid sequence represented by SEQ ID NO: 3;

(f1) substitution of Thr with Arg at a position corresponding to position 23 of the amino acid sequence represented by SEQ ID NO: 3;

(f2) substitution of Thr with Leu at a position corresponding to position 23 of the amino acid sequence represented by SEQ ID NO: 3;

(f3) substitution of Thr with Ser at a position corresponding to position 23 of the amino acid sequence represented by SEQ ID NO: 3;

(g6) a combination of (f1) and (e2);

(g7) a combination of (f2) and (e2); and

(g8) a combination of (f3) and (e2).

5. The protein of claim 1 , wherein the at least one mutation comprises substitution of amino acid residues at positions corresponding to at least two of positions 3, 6, 24, 25, 39, 46, 4, 49, 58, and 23 of the amino acid sequence represented by SEQ ID NO: 3 with other amino acid residues, deletion of the amino acid residues at the positions, or insertion of other amino acid residues into positions in front of or behind the positions.

6. The protein of claim 5 , wherein the at least one mutation is any one of the (a23) to (a28), or a combination of any one of the (a1) to (a6), (a23) to (a28) and any one or more of the (b1) to (f3).

7. The protein of claim 1 , wherein the identity of the amino acid sequence is at least 90%.

8. The protein of claim 1 , wherein the polypeptide chain further comprises substitution of an amino acid residue at a position corresponding to position 1 of the amino acid sequence represented by SEQ ID NO: 3 with Val and/or substitution of an amino acid residue at a position corresponding to position 29 of the amino acid sequence represented by SEQ ID NO: 3 with Ala.

9. The protein of claim 1 , wherein at least two of the polypeptide chains are contained.

10. A polynucleotide, encoding the immunoglobulin-binding protein of claim 1 .

11. A vector, comprising the polynucleotide of claim 10 .

12. A transformant, comprising the vector of claim 11 .

13. An affinity carrier, comprising:

a solid carrier; and

the protein of claim 1 , bound to the solid carrier.

14. A chromatography column, comprising:

the affinity carrier of claim 13 .

15. A method for isolating an antibody or a fragment thereof, the method comprising:

contacting the antibody or the fragment with the affinity carrier of claim 13 or a chromatography column comprising the affinity carrier.

16. A method for producing an immunoglobulin-binding protein, the method comprising:

expressing the immunoglobulin-binding protein of claim 1 in a transformant comprising a vector comprising a polynucleotide, encoding the immunoglobulin-binding protein or a cell-free protein synthesis system, or chemically synthesizing the immunoglobulin-binding protein.

17. A method for producing a mutant polypeptide chain, the method comprising:

introducing at least one mutation into a polypeptide chain consisting of an amino acid sequence represented by at least 85% identity to any one of SEQ ID NOs: 1 to 6, 57 to 59 and 61-62, wherein the mutation is a substitution of Asn with Gln at a position corresponding to position 11 of the amino acid sequence represented by SEQ ID NO: 1, 2, 3, 5, or at position 6 of the amino acid sequence represented by SEQ ID No. 4, or at position 9 of the amino acid sequence represented by SEQ ID No. 6, or at position 7 of the amino acid sequence represented by SEQ ID No. 57, 58, 59, 61, 62 and optionally having at least one mutation selected from the group consisting of (a) to (f):

(a) substitution of an amino acid residue at at least one position selected from the group consisting of positions corresponding to positions 3 and 6 of the amino acid sequence represented by SEQ ID NO: 3 with another amino acid residue, deletion of the amino acid residue at the at least one position, or insertion of another amino acid residue into a position in front of or behind the at least one position;

(b) substitution of an amino acid residue at at least one position selected from the group consisting of positions corresponding to positions 24 and 25 of the amino acid sequence represented by SEQ ID NO: 3 with another amino acid residue, deletion of the amino acid residue at the at least one position, or insertion of another amino acid residue into a position in front of or behind the at least one position;

(c) substitution of an amino acid residue at a position corresponding to position 39 of the amino acid sequence represented by SEQ ID NO: 3 with another amino acid residue, deletion of the amino acid residue at the position corresponding to position 39, or insertion of another amino acid residue into a position in front of or behind the position corresponding to position 39;

(d) substitution of an amino acid residue at a position corresponding to position 46 of the amino acid sequence represented by SEQ ID NO: 3 with another amino acid residue, deletion of the amino acid residue at the position corresponding to position 46, or insertion of another amino acid residue into a position in front of or behind the position corresponding to position 46;

(e) substitution of an amino acid residue at at least one position selected from the group consisting of positions corresponding to positions 4, 49, and 58 of the amino acid sequence represented by SEQ ID NO: 3 with another amino acid residue, deletion of the amino acid residue at the at least one position, or insertion of another amino acid residue into a position in front of or behind the at least one position; and

(f) substitution of an amino acid residue at a position corresponding to position 23 of the amino acid sequence represented by SEQ ID NO: 3 with another amino acid residue, deletion of the amino acid residue at the position corresponding to position 23, or insertion of another amino acid residue into a position in front of or behind the position corresponding to position 23.

18. A method for producing an affinity carrier, the method comprising:

immobilizing the immunoglobulin-binding protein of claim 1 on a solid carrier.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 3, 2026
From: MERCK LIFE SCIENCE KGAA
To: MERCK PATENT GMBH
Reel/Frame 074837/0686 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2026
From: JSR CORPORATION
To: MERCK LIFE SCIENCE KGAA
Reel/Frame 074403/0101 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2025
From: JSR MICRO N.V.; JSR LIFE SCIENCES, LLC
To: JSR CORPORATION
Reel/Frame 073153/0584 →
MERGER AND CHANGE OF NAME Recorded Feb 18, 2025
From: JSR CORPORATION; JICC-02 CO., LTD.
To: JSR CORPORATION
Reel/Frame 070242/0547 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2021
From: JSR MICRO, INC.
To: JSR LIFE SCIENCES, LLC
Reel/Frame 057092/0068 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 16, 2021
From: HAGA, TOMOAKI; ONOGI, SHUNSUKE; NAKAMURA, SATOSHI; HONDA, TOSHINARI; KAMIDE, TOMOYUKI
To: JSR CORPORATION; JSR MICRO INC.; JSR MICRO N.V.
Reel/Frame 055273/0585 →
Priority Claims (2)
JP 2018-157620 · Aug 24, 2018 · national
JP 2019-073529 · Apr 8, 2019 · national
Continuity (1)
Related Publication 20210179671A1 · Jun 17, 2021
References Cited (41)
US 20050143566A1 · Hober · 2005 [cited by applicant]
US 20100221844A1 · Bian et al. · 2010 [cited by applicant]
US 20100286373A1 · Majima et al. · 2010 [cited by applicant]
US 20120149875A1 · Johansson et al. · 2012 [cited by applicant]
US 20140005357A1 · Nakamura et al. · 2014 [cited by applicant]
US 20140100356A1 · Yoshida et al. · 2014 [cited by applicant]
US 20160159855A1 · Rodrigo et al. · 2016 [cited by applicant]
US 20160215026A1 · Yoshida · 2016 [cited by examiner]
US 20170333811A1 · Yoda et al. · 2017 [cited by applicant]
US 20170334954A1 · Rodrigo et al. · 2017 [cited by applicant]
US 20180044374A1 · Forss · 2018 [cited by examiner]
US 20190202871A1 · Shin et al. · 2019 [cited by applicant]
EP 3255058A1 · 2017 [cited by applicant]
EP 3276002A1 · 2018 [cited by applicant]
JP 2005538693A · 2005 [cited by applicant]
JP 2007252368A · 2007 [cited by applicant]
JP 201081866A · 2010 [cited by applicant]
JP 2010156687A · 2010 [cited by applicant]
JP 2012515160A · 2012 [cited by applicant]
JP 2014508118A · 2014 [cited by applicant]
JP 2016523959A · 2016 [cited by applicant]
JP 2017533924A · 2017 [cited by applicant]
WO WO0023580A1 · 2000 [cited by applicant]
WO WO03080655A1 · 2003 [cited by applicant]
WO WO2006092338A2 · 2006 [cited by applicant]
WO WO2007067596A2 · 2007 [cited by applicant]
WO WO2007067596A3 · 2007 [cited by applicant]
WO WO2012033446A1 · 2012 [cited by applicant]
WO WO2012133342A1 · 2012 [cited by applicant]
WO WO2013109302A2 · 2013 [cited by applicant]
WO WO2014046278A1 · 2014 [cited by applicant]
WO WO2015034056A1 · 2015 [cited by applicant]
WO WO2016125811A1 · 2016 [cited by applicant]
WO WO2018009006A1 · 2018 [cited by applicant]
International Search Report issued on Oct. 8, 2019 in PCT/JP2019/033138 filed on Aug. 23, 2019, 4 pages. [cited by applicant]
Hober et al., “Protein A chromatography for antibody purification”, Journal of Chromatography B, 2007, vol. 848, pp. 40-47. [cited by applicant]
Partial Supplementary European Search Report issued on Aug. 26, 2022, in corresponding European Patent Application No. 19851068.7, 17 pages. [cited by applicant]
Masoumeh Nosrati, et al., “Insights from engineering the Affibody-Fc interaction with a computational-experimental method”, Protein Engineering, Design and Selection, vol. 30, No. 9, Sep. 1, 2017, pp. 593-601, XP5595162… [cited by applicant]
Elin Gunneriusson, et al., “Staphylococcal Surface Display of Immunoglobulin A (IgA)- and IgE-Specific In Vitro-Selected Binding Proteins (Affibodies) Based on [cited by applicant]
Extended European Search Report issued Dec. 16, 2022 in European Patent Application No. 19851068.7, 17 pages. [cited by applicant]
Japanese Office Action issued on Jan. 24, 2023 in Japanese Patent Application 2020-538498, (with unedited computer-generated English translation), 29 pages. [cited by applicant]